Otilonium Bromide: High-Purity Antimuscarinic Agent for Advanced Neuroscience and Smooth Muscle Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄) is a highly pure, solid-state antimuscarinic agent used in neuroscience and smooth muscle research (APExBIO product page). It acts by inhibiting acetylcholine receptors (AChRs), enabling precise modulation of cholinergic signaling pathways in in vitro and in vivo models (internal reference). The compound exhibits robust solubility (≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol) and is supplied at ≥98% purity for experimental reproducibility. APExBIO’s B1607 SKU is intended for research use only and is not approved for clinical or diagnostic applications. Short-term solution stability (< -20°C) is essential to maintain pharmacological efficacy.

Biological Rationale

Otilonium Bromide is a quaternary ammonium compound that selectively blocks muscarinic acetylcholine receptors in smooth muscle tissue. This inhibition interrupts cholinergic neurotransmission, a key pathway underlying smooth muscle contraction and gastrointestinal motility (Otilonium Bromide: A Precision AChR Inhibitor). The ability to precisely modulate muscarinic receptor activity is critical for dissecting the mechanisms of GI motility disorders and for advanced modeling of cholinergic signaling in neuroscience.

Cholinergic signaling is central to neurogastroenterology, cognitive processes, and autonomic regulation. Disruption or hyperactivity of these pathways contributes to gastrointestinal motility disorders, smooth muscle spasms, and certain neurological pathologies. Otilonium Bromide's pharmacological selectivity makes it a preferred tool for isolating muscarinic components from broader cholinergic effects (internal reference).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts primarily as a competitive antagonist at muscarinic acetylcholine receptors (AChRs) in smooth muscle cells. By binding to the receptor, it prevents acetylcholine from activating downstream G-protein coupled signaling cascades. This results in reduced intracellular Ca²⁺ influx, decreased phosphorylation of myosin light chains, and subsequent inhibition of muscle contraction (Vijayan et al., 2021).

• The compound does not cross the blood-brain barrier, confining its activity to peripheral tissues under standard concentrations (internal reference).
• In experimental GI models, otilonium bromide reduces motility and spasm frequency by targeting M2 and M3 muscarinic receptor subtypes on smooth muscle.
• It displays minimal affinity for nicotinic acetylcholine receptors, ensuring receptor-class specificity (APExBIO).

This mechanism underpins its widespread use in gastrointestinal motility disorder models and as a reference AChR inhibitor in neuroscience research.

Evidence & Benchmarks

• Otilonium Bromide inhibits muscarinic acetylcholine receptor-mediated contractions in isolated rat ileum, with IC₅₀ values typically in the low micromolar range at 37°C, pH 7.4 (Smith et al., 2020, DOI).
• Solubility studies report ≥55.8 mg/mL in water at 25°C, supporting its use in high-concentration in vitro experiments (APExBIO).
• Purity analysis by HPLC confirms ≥98% batch-to-batch consistency for the B1607 product (APExBIO).
• Compared to other antimuscarinics, otilonium bromide exhibits negligible central nervous system penetration due to its quaternary structure, reducing off-target effects (internal reference).
• Short-term solution stability is optimal at -20°C for up to 7 days; longer storage or repeated freeze-thaw cycles lead to decomposition and loss of activity (APExBIO).

This article extends prior summaries (internal article) by providing updated solubility and purity benchmarks, and by contrasting otilonium bromide’s peripheral selectivity versus other antimuscarinics.

Applications, Limits & Misconceptions

Otilonium Bromide is validated for the following core research applications:

• Pharmacological modeling of smooth muscle spasms in GI motility disorder research.
• Dissection of cholinergic signaling pathways in neuronal and non-neuronal cells.
• Use as a reference compound for benchmarking new antimuscarinic agents (internal reference).
• Integration into translational models of gastrointestinal and neurological disease.

Limits:

• Not approved for diagnostic or therapeutic use in humans or animals (APExBIO).
• Does not cross the blood-brain barrier at standard concentrations.
• Activity is restricted to muscarinic, not nicotinic, acetylcholine receptors.

Common Pitfalls or Misconceptions

• Clinical Use: Otilonium Bromide from APExBIO is for research only; it is not suitable for clinical or diagnostic applications.
• CNS Effects: The compound has negligible central nervous system activity due to poor BBB penetration.
• Receptor Specificity: It does not inhibit nicotinic acetylcholine receptors; use alternate agents for nicotinic pathway studies.
• Storage: Prolonged exposure to room temperature or repeated freeze-thaw cycles degrades activity.
• Solubility: Solubility parameters are solvent-specific; exceeding recommended concentrations can lead to precipitation.

Workflow Integration & Parameters

Otilonium Bromide (B1607) is supplied as a crystalline solid with ≥98% purity. Store at -20°C in a dry, inert atmosphere. Prepare stock solutions in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), or ethanol (≥91 mg/mL). Use solutions within 7 days for maximal efficacy. For in vitro assays, dilute to desired working concentration (typically 0.1–10 μM) in physiological buffers at pH 7.2–7.4.

For tissue bath experiments, preincubate tissues for at least 10 minutes with otilonium bromide to ensure receptor occupancy. For cell signaling assays, confirm absence of cytotoxicity at selected concentrations. Always include vehicle controls and document solvent composition.

This article updates prior workflow guidance (internal reference) by specifying solvent-dependent stock concentrations and emphasizing solution stability constraints.

Conclusion & Outlook

Otilonium Bromide remains a gold-standard antimuscarinic agent for neuroscience and smooth muscle research due to its high purity, robust solubility, and selective inhibition of muscarinic acetylcholine receptors. Its product specification and proven pharmacological profile, as provided by APExBIO, support reliable and reproducible research in cholinergic signaling and gastrointestinal motility models. Researchers are advised to adhere strictly to recommended storage and handling parameters to preserve compound integrity. Future directions include expanded benchmarking in disease-relevant models and integration with high-throughput screening platforms. For further technical details, refer to the Otilonium Bromide product page and peer-reviewed literature.